Summary & Overview
CPT 0176U: IBSchek® Immunoassay for CdtB and Vinculin IgG Antibodies
CPT code 0176U is a Proprietary Laboratory Analyses (PLA) code for the IBSchek® immunoassay from Commonwealth Diagnostics International, which measures CdtB and vinculin IgG antibodies as biomarkers that may indicate irritable bowel syndrome (IBS). Nationally, PLA CPT codes like 0176U matter because they identify single-source, manufacturer- or lab-specific tests and are used in reporting and claims adjudication for novel diagnostic services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, and which major payers are included in the coverage discussion. The publication also outlines expected benchmarks for billing and coding behavior, summarizes relevant policy and reimbursement considerations affecting PLA tests, and provides clinical context for when this immunoassay is used in diagnostic workflows.
This summary is intended for billing managers, laboratory directors, and policy analysts seeking a national-level briefing on CPT code 0176U—what it represents, who covers it in major payer portfolios, and the types of operational and policy topics that follow in the full publication.
Billing Code Overview
CPT code 0176U is a Proprietary Laboratory Analyses (PLA) code assigned to the IBSchek® immunoassay produced by Commonwealth Diagnostics International. The test evaluates the presence of CdtB and vinculin IgG antibodies in a patient’s bloodstream to help identify biomarkers associated with irritable bowel syndrome (IBS).
Service type: Laboratory immunoassay diagnostic test
Typical site of service: Clinical laboratory or outpatient laboratory collection site
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient presents to a gastroenterology clinic with a 2-year history of recurrent abdominal pain, bloating, and alternating constipation and diarrhea. Prior workup including stool studies, basic labs, celiac serology, and colonoscopy with biopsies were unrevealing for inflammatory bowel disease, celiac disease, or infection. The gastroenterologist considers post-infectious irritable bowel syndrome (IBS) as a working diagnosis and orders the proprietary immunoassay test IBSchek® to evaluate for serum IgG antibodies to cytolethal distending toxin B (CdtB) and vinculin.
The clinical workflow: the provider documents symptoms, prior negative evaluations, and orders test 0176U in the electronic medical record with appropriate specimen collection instructions. A peripheral blood specimen is drawn at the clinic or an outpatient lab collection site (typical site of service: outpatient clinic or independent laboratory). The specimen is sent to Commonwealth Diagnostics International for analysis. Results reporting includes qualitative/quantitative antibody levels and interpretive guidance indicating whether antibody patterns are consistent with IBS. The ordering provider reviews results, documents interpretation in the medical record, and integrates findings into the diagnostic formulation and management planning for the patient.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard reporting indicator |